Fluorescence spectroscopic investigation of competitive interactions between ochratoxin A and 13 drug molecules for binding to human serum albumin

Luminescence

Volumn 28, Issue 5, 2013, Pages 726-733

  Poõr, Miklõs ^a   Kunsági Máté, Sándor ^a   Czibulya, Zsuzsanna ^a   Li, Yin ^a   Peles Lemli, Beáta ^a   Petrik, Jõzsef ^b   Vladimir Kneževic̈, Sanda ^b   Koszegi, Tamás ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

competitive interaction; drug molecules; fluorescence polarization; human serum albumin; ochratoxin A

Indexed keywords

ANIMALS; BEVERAGES; BINDING SITES; BODY FLUIDS; DRUG INTERACTIONS; FLUORESCENCE; MOLECULES; POLARIZATION; TOXICITY;

ANIMAL FEED; BALKANS; COMPETITIVE INTERACTIONS; DRUG MOLECULES; FLUORESCENCE POLARIZATION; FOOD ANIMALS; HUMAN SERUM ALBUMINS; NEPHROPATHY; OCHRATOXIN A; SPECTROSCOPIC INVESTIGATIONS;

MYCOTOXINS;

ANIMALIA;

DRUG; HUMAN SERUM ALBUMIN; OCHRATOXIN; SERUM ALBUMIN;

ARTICLE; BINDING SITE; CHEMISTRY; COMPETITIVE INTERACTION; DRUG MOLECULES; FLUORESCENCE POLARIZATION; HUMAN; SPECTROFLUOROMETRY;

COMPETITIVE INTERACTION; DRUG MOLECULES; FLUORESCENCE POLARIZATION; HUMAN SERUM ALBUMIN; OCHRATOXIN A;

BINDING SITES; HUMANS; OCHRATOXINS; PHARMACEUTICAL PREPARATIONS; SERUM ALBUMIN; SPECTROMETRY, FLUORESCENCE;

EID: 84878225460     PISSN: 15227235     EISSN: 15227243     Source Type: Journal    
DOI: 10.1002/bio.2423     Document Type: Article

References (48)

1. Van Der Merwe KJ, Steyn PS, Fourie L,. Part II. The constitution of ochratoxins A, B, and C, metabolites of Aspergillus ochraceus wilh. J Chem Soc 1965; 7083-8.
2. Pohland AE, Nesheim S, Friedman L, Ochratoxin A: a review. Pure Appl Chem 1992; 64: 1029-46.
3. Duarte SC, Pena A, Lino CM,. Ochratoxin A non-conventional exposure sources-A review. Microchem J 2009; 93: 115-20.
4. Kuiper-Goodman T, Scott PM,. Risk assessment of ochratoxin A: an update. Food Addit Contam 1996; 13: 53-7.
5. Coronel MB, Sanchis V, Ramos AJ, Marin S,. Review. Ochratoxin A: Presence in Human Plasma and Intake Estimation. Food Sci Tech Int 2010; 16: 5-18.
6. Amezqueta S, Gonzalez-Penas E, Murillo-Arbizu M, de Cerain AL,. Ochratoxin A decontamination: A review. Food Contr 2009; 20: 326-33.
7. Bozic Z, Duancic V, Kraus O, Skljarov I,. Balkan endemic nephropathy: still a mysterious disease. Eur J Epidemiol 1995; 11: 235-8.
8. Tatu CA, Orem WH, Finkelman RB, Feder GL,. The etiology of Balkan endemic nephropathy: still more questions than answers. Environ Health Perspect 1998; 106: 689-700.
9. Gagliano N, Donne ID, Torri C, Migliori M, Grizzi F, Milzani A, et al,. Early cytotoxic effects of ochratoxin A in rat liver: A morphological, biochemical and molecular study. Toxicol 2006; 225: 214-24.
10. Sava V, Reunova O, Velasquez A, Harbison R, Sánchez-Ramos J,. Acute neurotoxic effects of the fungal metabolite ochratoxin-A. Neurotoxicology 2006; 27: 82-92.
11. Odhav B, Adam JK, Bhoola KD,. Modulating effects of fumonisin B1 and ochratoxin A on leukocytes and messenger cytokines of the human immune system. Int Immunopharmacol 2008; 8: 799-809.
12. Chernozemsky IN,. Balkan endemic nephropathy and the associated tumours of the urinary system: a summary of epidemiological features in Bulgaria. IARC Sci Publ 1991; 115: 3-4.
13. Pfohl-Leszkowicz A, Manderville RA,. An update on direct genotoxicity as a molecular mechanism of ochratoxin A carcinogenicity. Chem Res Toxicol 2012; 25: 252-62.
14. Ringot D, Chango A, Schneider YJ, Larondelle Y,. Toxicokinetics and toxicodynamics of ochratoxin A, an update. Chem Biol Interact 2006; 159: 18-46.
15. 2 phase arrest in human gastric epithelium GES-1 cells in vitro. Toxicol Lett 2010; 193: 152-8.
16. 2 phase arrest in human gastric epithelium cells. Toxicol Lett 2012; 209: 186-92.
17. Li J, Yin S, Dong Y, Fan L, Hu H,. p53 activation inhibits ochratoxin A-induced apoptosis in monkey and human kidney epithelial cells via suppression of JNK activation. Biochem Biophys Res Commun 2011; 411: 458-63.
18. Fusi E, Cheli F, Rebucci R, Pecorini C, Galante F, Rossi L, et al,. Role of alpha-tocopherol in counteracting DNA damage induced by Ochratoxin A in primary porcine fibroblasts. Ital J Anim Sci 2009; 8: 301-3.
19. Costa S, Utan A, Cervellati R, Speroni E, Guerra MC,. Catechins: natural free-radical scavengers against ochratoxin A-induced cell damage in a pig kidney cell line (LLC-PK1). Food Chem Toxicol 2007; 45: 1910-17.
20. Abdel-Wahhab MA, Abdel-Azim SH, El-Nekeety AA,. Inula crithmoides extract protects against ochratoxin A-induced oxidative stress, clastogenic and mutagenic alterations in male rats. Toxicon 2008; 52: 566-73.
21. Creppy EE, Baudrimont I, Belmadani A, Beteder AM,. Aspartam as a preventive agent of chronic toxic effects of Ochratoxin A in experimental animals. J Toxicol Tox Rev 1996; 15: 207-21.
22. Obrecht-Pflumio S, Grosse Y, Pfohi-Leszkowicz A, Dirheimer G,. Protection by indomethacin and aspirin against genotoxicity of ochratoxin A, particularly in the urinary bladder and kidney. Arch Toxicol 1996; 70: 244-8.
23. Il'ichev YV, Perry JL, Simon JD,. Interaction of ochratoxin A with human serum albumin. Preferential binding of the dianion and pH effects. J Phys Chem B 2002; 106: 452-9.
24. Il'ichev YV, Perry JL, Simon JD,. Interaction of ochratoxin A with human serum albumin. A common binding site of ochratoxin A and warfarin in subdomain IIA. J Phys Chem B 2002; 106: 460-5.
25. Hagelberg S, Hult K, Fuchs R,. Toxicokinetics of ochratoxin A in several species and its plasma-binding properties. J Appl Toxicol 1989; 9: 91-6.
26. Studer-Rohr I, Schlatter J, Dietrich DR,. Kinetic parameters snd intraindividual fluctuations of Ochratoxin A plasma levels in human. Arch Toxicol 2000; 74: 499-510.
27. Peraica M, Domijan AM, Fuchs R, Lucic A, Radic B,. The occurrence of ochratoxin A in blood in general population of Croatia. Toxicol Lett 1999; 110: 105-12.
28. Lino CM, Baeta ML, Henri M, Dinis AMP, Pena AS, Silveira MIN,. Levels of ochratoxin A in serum from urban and rural Portuguese populations and estimation of exposure degree. Food Chem Toxicol 2008; 46: 879-85.
29. Hmaissia Khlifa K, Ghali R, Mazigh C, Aouni Z, Machgoul S, Hedhili A,. Ochratoxin A levels in human serum and foods from nephropathy patients in Tunisia: Where are you now? Exp Toxicol Pathol 2012; 64 (5): 509-12.
30. Baudrimonta I, Murnb M, Betheder AM, Guilcher J, Creppy EE,. Effect of piroxicam on the nephrotoxicity induced by ochratoxin A in rats. Toxicology 1995; 95; 147-54.
31. Galtier P, Camguilhem R, Bodin G,. Evidence for in vitro and in vivo interaction between Ochratoxin A and three acidic drugs. Food Cosmet Toxicol 1980; 18: 493-6.
32. Kumagai S,. Ochratoxin A: Plasma concentration and excretion into bile and urine in albumin-deficient rats. Food Chem Toxicol 1985; 23: 941-3.
33. Hardman JG, Limbird LE, Goodman Gilman A,. Goodman and Gilman's The pharmacological basis of therapeutics, 10th edn. New York: The McGraw-Hill Companies, 2001: 1924-2021.
34. Higham C, Aarons L, Holt PJ, Lynch M, Rowland M,. A chronic dose-ranging study of the pharmacokinetics of phenylbutazone in rheumatoid arthritic patients. Br J Clin Pharmacol 1981; 12: 123-9.
35. Bojko B, Sułkowska A, Macia̧zek M, R'ownicka J, Njau F, Sułkowski WW,. Changes of serum albumin affinity for aspirin induced by fatty acid. Int J Biol Macromol 2008; 42: 314-23.
36. Li ZM, Wei CW, Zhang Y, Wang DS, Liu YN,. Investigation of competitive binding of ibuprofen and salicylic acid with serum albumin by affinity capillary electrophoresis. J Chromat B 2011; 879: 1934-8.
37. Russeva V, Mihailova D,. Modelling of indometacin and diclofenac sodium binding to the molecule of human serum albumin. Arzneim-Forsch/Drug Res 1996; 46: 288-92.
38. Bojko B, Sułkowska A, Macia̧zek-Jurczyk M, Rownicka J, Pentak D, Sułkowski WW,. Alterations of furosemide binding to serum albumin induced by increased level of fatty acid. J Pharma Biomed Analys 2010; 51: 273-7.
39. Seedher N, Kanojia M,. Mechanism of interaction of hypoglycemic agents glimepiride and glipizide with human serum albumin. Cent Eur J Chem 2009; 7: 96-104.
40. Otto J, Lesko LJ,. Protein binding of nifedipine. J Pharm Pharmac 1986; 38: 399-400.
41. Russeva V, Mihailova D., Binding of phenylbutazone to human serum albumin. Characterization and identification of binding sites. Arzneim-Forsch/Drug Res 1999; 49: 255-8.
42. Chen J, Ohnmacht C, Hage DS,. Studies of phenytoin binding to human serum albumin by high-performance affinity chromatography. J Chromat B 2004; 809: 137-45.
43. Zhang HM, Chen TT, Zhou QH, Wang YQ,. Binding of caffeine, theophylline, and theobromine with human serum albumin: A spectroscopic study. J Mol Struct 2009; 938: 221-8.
44. Mallik R, Yoo MJ, Chen S, Hage DS,. Studies of verapamil binding to human serum albumin by high-performance affinity chromatography. J Chromat B 2008; 876: 69-75.
45. Fujiwara S, Amisaki T,. Steric and Allosteric Effects of Fatty Acids on the Binding of Warfarin to Human Serum Albumin Revealed by Molecular Dynamics and Free Energy Calculations. Chem Pharm Bull 2011; 59 (7): 860-7.
46. Il'ichev YV, Perry JL, Rüker F, Dockal M, Simon JD,. Interaction of ochratoxin A with human serum albumin. Binding sites localized by competitive interactions with the native protein and its recombinant fragments. Chem Biol Interact 2002; 141: 275-93.
47. Gans P, Sabatini A, Vacca A,. Hyperquad2006, version 3.1.60; Protonic Software. 2006.
48. Perry JL, Christensen T, Goldsmith MR, Toone EJ, Beratan DN, Simon JD,. Binding of ochratoxin A to human serum albumin stabilized by a protein-ligand ion pair. J Phys Chem B 2003; 107: 7884-8.